Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Ifosfamide and Carboplatin for Recurrent Pediatric Germ Cell Tumors
NCT00467051Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2007
- Primary completion
- Mar 2012
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, ifosfamide and carboplatin in malignant germ cell tumor (MGCT), sponsored by Children's Oncology Group. Primary endpoint: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria at 42 days. Started Nov 2007; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionifosfamidecarboplatin
03
Conditions
malignant germ cell tumor (MGCT)
Beyond the preview
Go deeper on NCT00467051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467051.